Safety and Efficacy of ADSTEM Inj. in Patients With Moderately Subacute and Chronic Atopic Dermatitis
Status:
Completed
Trial end date:
2017-12-01
Target enrollment:
Participant gender:
Summary
This study aims to evaluate safety, tolerance, and efficacy in subjects with over moderately
subacute and chronic atopic dermatitis after an intravenous injection of autologous
mesenchymal stem cells. The study is composed of two steps. Step 1 is to determine clinically
proper dose capacity of the ADSTEM Inj. and step 2 is to evaluate exploratory efficacy of the
ADSTEM Inj. at the proper dose.